Literature DB >> 11310211

Increased expression of cyclooxygenase-2 and nitric oxide synthase-2 in human prostate cancer.

P Uotila1, E Valve, P Martikainen, M Nevalainen, M Nurmi, P Härkönen.   

Abstract

Cyclooxygenase-1 (COX-1), cyclooxygenase-2 (COX-2) and inducible nitric oxide synthase-2 (NOS-2) each have an important role in angiogenesis. The expression of these genes was investigated in human prostate cancer by immunohistochemistry, the expression of COX-1 and COX-2 being confirmed by mRNA analysis. Prostate cancer specimens from 12 patients were compared to control prostates from 13 patients operated on for bladder carcinoma. The intensity of COX-2 and NOS-2 immunostaining was significantly stronger in prostate cancer cells than in the non-malignant glandular epithelium of the control prostates. COX-2 and NOS-2 were clearly also expressed in the lesions of prostatic intraepithelial neoplasia (PIN) in control prostates. COX-2 was detected in the muscle fibres of the hyperplastic stroma of some control prostates. No significant difference was detected in COX-1 expression between control and cancer prostates. These results indicate that the expression of COX-2 and NOS-2 is elevated in prostatic adenocarcinoma and in PIN.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11310211     DOI: 10.1007/s002400000148

Source DB:  PubMed          Journal:  Urol Res        ISSN: 0300-5623


  39 in total

Review 1.  COX-2 and cancer: a new approach to an old problem.

Authors:  Y S Bakhle
Journal:  Br J Pharmacol       Date:  2001-11       Impact factor: 8.739

Review 2.  Cyclooxygenase-2 and thromboxane synthase in non-endocrine and endocrine tumors: a review.

Authors:  Onder Onguru; Mary B Casey; Sabine Kajita; Nobuki Nakamura; Ricardo V Lloyd
Journal:  Endocr Pathol       Date:  2005       Impact factor: 3.943

3.  Maintenance of androgen receptor inactivation by S-nitrosylation.

Authors:  Yu Qin; Anindya Dey; Hamsa Thayele Purayil; Yehia Daaka
Journal:  Cancer Res       Date:  2013-10-11       Impact factor: 12.701

4.  Neamine is preferential as an anti-prostate cancer reagent by inhibiting cell proliferation and angiogenesis, with lower toxicity than cis-platinum.

Authors:  Ya-Ping Liu; Guo-Fu Hu; Yun-Xia Wu
Journal:  Oncol Lett       Date:  2015-05-19       Impact factor: 2.967

5.  Roles of Eicosanoids in Prostate Cancer.

Authors:  Kasem Nithipatikom; William B Campbell
Journal:  Future Lipidol       Date:  2008-08-01

6.  Multifaceted preventive effects of single agent quercetin on a human prostate adenocarcinoma cell line (PC-3): implications for nutritional transcriptomics and multi-target therapy.

Authors:  Mohammad R Noori-Daloii; Majid Momeny; Mehdi Yousefi; Forough Golsaz Shirazi; Mehdi Yaseri; Nasrin Motamed; Nazanin Kazemialiakbar; Saeed Hashemi
Journal:  Med Oncol       Date:  2010-07-02       Impact factor: 3.064

7.  Atorvastatin and celecoxib in combination inhibits the progression of androgen-dependent LNCaP xenograft prostate tumors to androgen independence.

Authors:  Xi Zheng; Xiao-Xing Cui; Zhi Gao; Yang Zhao; Yong Lin; Weichung Joe Shih; Mou-Tuan Huang; Yue Liu; Arnold Rabson; Bandaru Reddy; Chung S Yang; Allan H Conney
Journal:  Cancer Prev Res (Phila)       Date:  2010-01

8.  Comprehensive identification and modified-site mapping of S-nitrosylated targets in prostate epithelial cells.

Authors:  Ying Wai Lam; Yong Yuan; Jared Isaac; C V Suresh Babu; Jarek Meller; Shuk-Mei Ho
Journal:  PLoS One       Date:  2010-02-05       Impact factor: 3.240

9.  Celecoxib induces apoptosis in cervical cancer cells independent of cyclooxygenase using NF-kappaB as a possible target.

Authors:  Su-Hyeong Kim; Sang-Hyun Song; Sang-Gyun Kim; Kyung-Soo Chun; So-Young Lim; Hye-Kyung Na; Jae Weon Kim; Young-Joon Surh; Yung-Jue Bang; Yong-Sang Song
Journal:  J Cancer Res Clin Oncol       Date:  2004-06-10       Impact factor: 4.553

10.  Prognostic Significance and Clinicopathological Associations of COX-2 SNP in Patients with Nonsmall Cell Lung Cancer.

Authors:  Peter P Grimminger; Jan Stöhlmacher; Daniel Vallböhmer; Paul M Schneider; Arnulf H Hölscher; Ralf Metzger; Peter V Danenberg; Jan Brabender
Journal:  J Oncol       Date:  2009-11-22       Impact factor: 4.375

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.